Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  SciBase Holding AB (publ)    SCIB   SE0007045414

SCIBASE HOLDING AB (PUBL) (SCIB)
My previous session
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

SciBase publ : Goldenberg Dermatology first in the US to offer SciBase's Nevisense screening for early detection of melanoma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 04:01pm CEST

November 9thSciBase announced that the Company had received the first order in the US from Goldenberg Dermatology, a premier New York City dermatology practice of Dr. Gary Goldenberg and Dr. Kristina Goldenberg. The order, consisting of a Nevisense system and single-use electrodes, means that Drs. Goldenberg will be the first dermatologists in the US to be able to offer the Nevisense test for early detection of melanoma and atypical moles (nevi). Earlier this fall, at the Fall Clinical Dermatology Conference SciBase was mentioned as one of the ten most important new technologies within skin cancer detection. 

-We are very pleased to welcome Dr. Gary Goldenberg and Dr. Kristina Goldenberg as our first customers in the US. Goldenberg Dermatology is a perfect first customer for us as they perfectly fit the profile of our primary target group as stated in our launch and growth strategy. Goldenberg Dermatology is a renowned clinic with focus on personalized dermatology and cancer prevention and early detection. We are very much looking forward to working together in spreading the word about Nevisense and its advantages, says Simon Grant, CEO SciBase.

Goldenberg Dermatology, office of Dr. Gary Goldenberg and Dr. Kristina Goldenberg, is a comprehensive medical and cosmetic dermatology practice. By taking a very personalized and customized approach within the practice, this husband and wife team works with each patient, taking into account diet, lifestyle, and overall health, to formulate a long-term plan promoting optimal skin health. This holistic and integrative dermatology practice focuses on prevention and early detection of skin cancer, including melanoma, as well as other aspects of medical and cosmetic dermatology. The Goldenbergs strive to formulate an all-encompassing skin health treatment plan with regards to every patient's needs, concerns and well-being.

- Melanoma is one of the deadliest cancers in the US. Prevention and early detection of melanoma should be a focus of every dermatology practice. We are excited to be the first practice in USA to offer Nevisense to our patients. This device will allow us to focus on lesions that are abnormal and detect these at the earliest stage, potentially saving lives of our patients. It will also allow us to carefully monitor less atypical lesions, decreasing unnecessary biopsies and scarring. We look forward to using Nevisense, along with careful physical examination, dermascopy and photography, to offer the most comprehensive melanoma and dysplastic nevus detection approach available, says Gary Goldenberg, MD.

Dr. Gary Goldenberg is a medical and cosmetic dermatologist and an Assistant Clinical Professor of Dermatology at The Icahn School of Medicine at Mount Sinai Hospital in New York City. He is also the former Medical Director of the Dermatology Faculty Practice at The Mount Sinai Medical Center.

Board Certified in both Dermatology and Dermatopathology, Dr. Goldenberg provides comprehensive dermatological care in medical and cosmetic dermatology, including BOTOX® and filler injections, laser surgery, skin cancer, nevi (moles), psoriasis, acne, rosacea, eczema, and sexually transmitted diseases.

Dr. Goldenberg is the author of over 100 original articles, abstracts and book chapters. He regularly lectures at the American Academy of Dermatology Meetings, as well as other national and international dermatology meetings.

Dr. Goldenberg is frequently sought after by the media (http://goldenbergdermatology.com/media/) on cosmetic and medical dermatology topics and has appeared on CNN, Fox, ABC, NBC, Glamour, New Beauty, Redbook, Allure, Wall Street Journal, and many others.

Dr. Goldenberg is a member of the American Academy of Dermatology, American Society for Dermatologic Surgery, American Society of Dermatopathology, and served as the President (2015-2017) and member of the Executive Board of Directors for the Dermatologic Society of Greater New York, the national largest local dermatologic society.

- There is a melanoma epidemic in US. This is especially true in young women who use tanning beds or had sunburns before the age of 18. Every day we see young patients with atypical moles or even melanoma in our office. NeviSense will allow us to detect abnormal lesions early, potentially saving lives of our patients. For many, it will also decrease the need for unnecessary biopsies of less abnormal lesions, saving the patients from unneeded scarring. We look forward to using NeviSense in our practice and are excited to be the first practice in US to bring this potentially life-saving device to our patients, Kristina Goldenberg, MD.

Dr. Kristina Goldenberg is a trusted and dependable name in advanced dermatology. Dr. Goldenberg is a Board Certified Dermatologist, and Clinical Instructor of Dermatology at The Icahn School of Medicine at Mount Sinai Hospital in New York City. Dr. Goldenberg obtained her medical degree from the Albert Einstein College of Medicine of Yeshiva University, where she graduated with a Dean's Citation. She completed her dermatology training at the Icahn School of Medicine at Mount Sinai, where she served as Chief Resident.

Dr. Goldenberg cares for adult and pediatric patients and completed extensive training in medical and cosmetic dermatology. Her expertise are in medical dermatology, including acne, rosacea, eczema, psoriasis, and skin cancer, as well as cosmetic dermatology, including filler and botox injections, and laser surgery.

Dr. Goldenberg has appeared in numerous media outlets, including New York Times, Fox, Allure, Glamour, Byrdie, Self, and many others. Dr. Goldenberg is a member of the American Academy of Dermatology and Dermatologic Society of Greater New York.

Earlier this fall, SciBase participated in, exhibited and demonstrated their product Nevisense, for early detection of malignant melanoma at the Fall Clinical Dermatology Conference in Las Vegas. At the congress Nevisense was presented as one of the top ten most important news stories within skin cancer.

Goldenberg Dermatology is the first commercial customer in the US for SciBase and is of strategic importance. It can be seen as an early sign that our launch strategy is the right approach. SciBase's strategy focuses initially on marketing Nevisense to private concierge clinics in the New York Metropolitan Area. In addition SciBase will build awareness of Nevisense and further develop the existing network of Key Opinion Leaders (KOL) in the northeast region of the US. SciBase will also approach selected local and regional insurance companies and seek local reimbursement for EIS testing. To be able to expand nationwide in the US, SciBase intends to work with nationwide distribution partners, which will lead to a further acceleration of the sales growth.

For more information, please contact:
Simon Grant, CEO SciBase
Phone: +46 72 887 43 99
Email: simon.grant@scibase.com  

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB"). Avanza is the certified advisor. Further information is available on www.scibase.com.  

http://news.cision.com/scibase/r/goldenberg-dermatology-first-in-the-us-to-offer-scibase-s-nevisense-screening-for-early-detection-of,c2388261

http://mb.cision.com/Main/12371/2388261/749814.pdf

(c) 2017 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SCIBASE HOLDING AB (PUBL)
08/21SCIBASE PUBL : Interim report
AQ
06/21SCIBASE PUBL : releases major improvements to Nevisense
AQ
05/22SCIBASE PUBL : Improved accuracy and usability for SciBase Nevisense can create ..
AQ
05/16SCIBASE PUBL : Bulletin from annual general meeting of SciBase Holding AB (publ)..
AQ
05/09SCIBASE PUBL : Interim report
AQ
04/25SCIBASE PUBL : publishes the Annual report for 2017
AQ
04/09SCIBASE PUBL : NOTICE of the Annual General Meeting in SciBase Holding AB (publ)
PU
04/09SCIBASE PUBL : NOTICE   of the Annual General Meeting in SciBase Holding AB (pub..
AQ
02/20SCIBASE PUBL : Year-end Report
AQ
2017SCIBASE LETTER FROM THE CEO NO 5 : Launch of updated Strategy
AQ
More news
Financials (SEK)
Sales 2018 10,0 M
EBIT 2018 -39,0 M
Net income 2018 -38,5 M
Finance 2018 68,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 1,18x
EV / Sales 2019 2,13x
Capitalization 79,8 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 15,0  SEK
Spread / Average Target 213%
EPS Revisions
Managers
NameTitle
Simon James Grant President & Chief Executive Officer
Tord Bertil Lendau Chairman
Michael Colérus Chief Financial Officer
Renée Julie Elisabet Aguiar-Lucander Independent Director
Per Gunnar Ernst Aniansson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SCIBASE HOLDING AB (PUBL)9
SARTORIUS AG72.37%12 001
MYRIAD GENETICS, INC.37.92%3 281
VAREX IMAGING CORP-25.44%1 150
DIRUI INDUSTRIAL CO LTD--.--%701
OXFORD IMMUNOTEC GLOBAL PLC14.53%415